1 / 24

Affymetrix Gene Expression Microarrays

Affymetrix Gene Expression Microarrays. Application to Pulmonary Arterial Hypertension Bob Stearman 02/24/2014. Pulmonary Arterial Hypertension (PAH). Rare Disease: USA ~1000 new cases/ yr More Common in Females (2:1) with Earlier Presentation (30s-40s vs 40s-50s)

kiet
Download Presentation

Affymetrix Gene Expression Microarrays

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Affymetrix Gene Expression Microarrays Application to Pulmonary Arterial Hypertension Bob Stearman 02/24/2014

  2. Pulmonary Arterial Hypertension (PAH) Rare Disease: USA ~1000 new cases/yr More Common in Females (2:1) with Earlier Presentation (30s-40s vs 40s-50s) BMPR2 Mutations Found in HPAH with Incomplete Penetrance Combination Drug Therapy Common PDE5 and Endothelin Inhibitors plus Prostacyclin Slows Progression But No Cure (5-yr 66%) Elevations of Pulmonary Hemodynamics

  3. Pulmonary Arterial Hypertension (PAH) Vessel Thickening Muscularization (SMCs) Plexiform Lesion (ECs) Hyperproliferation of PAECs and SMCs Structural Changes in Lung Vasculature Stacher et al., AJRCCM 186, 261 (2012)

  4. Pulmonary Arterial Hypertension (PAH) Vessel Thickening vs mPAP (p-value 0.03; r=0.27) Perivascular Inflammation Elevation in Pulmonary Hemodynamics Echocardiogram and Right Heart Catherization Studies Increased Inflammation Stacher et al., AJRCCM 186, 261 (2012)

  5. Pulmonary Hypertension Breakthrough Initiative Multi-Center Lung Tissue Procurement 9 Geographically Spread Procurement Centers “Excessively” Complex Tissue Dissection 3+ Hours To Carryout 1 Central Tissue Repository Genomics Core & Secondary Tissue Repository (Frozen and RNALater) Rare Disease = Slow Recruitment

  6. PHBI Clinical Information Stacher et al., AJRCCM 186, 261 (2012)

  7. PHBI Pathological Information Vessel Thickness (measured and fractional) Total, Intima, Media, Internal Diameter Plexiform Lesions Number and Density Inflammation Thrombi Pulmonary Vein Remodeling Stacher et al., AJRCCM 186, 261 (2012)

  8. PHBI Lung Tissue Harvest RUL = right upper lobe RML = right middle lobe RLL = right lower lobe H= Hilum. Stacher et al., AJRCCM 186, 261 (2012)

  9. Pulmonary Hypertension Breakthrough Initiative: Sample Summary PAH Patients: End-stage disease getting transplant 4 General Types of PAH: HPAH, IPAH, APAH, Other Failed Donors (FDs; controls): No match for lungs but available for research Slow Recruitment: MAs run in 3 “annual” batches PAH: Female Bias (2:1 F:M) and older FDs: Male Bias (1:2 F:M) and younger compared to PAH

  10. QC QC QC QC QC Workflow of Gene Expression Biological question Experimental design Tissue / sample preparation Extraction of Total RNA Probe amplification & labeling Microarray hybridization & processing Image analysis Data analysis Expression measures - Normalization - Statistical Filtering - Clustering - Pathway analysis Biological Verification

  11. PAH Patients vs. FD Disease-specific gene expression patterns? 4 General Types of PAH: HPAH, IPAH, APAH, Other Will Gene Expression Patterns Detect Clinical Subclasses? PAH Patient Gender Bias PAH vs FD Gender and Age (?) Bias Microarrays run in 3 “annual” batches Different lots of arrays and reagents Changes in labeling methodology PHBI: Experimental Design

  12. PHBI Lung RNA Samples (in RNALater) Are Variable

  13. PHBI: Normalization Uncorrected PHBI Data

  14. PHBI: Normalization Corrected PHBI Data By Batch and Gender

  15. PHBI: Normalization Corrected PHBI Data By Batch and Gender Low Variance Genes Removed (33K->6K)

  16. PHBI: Clustering

  17. PHBI: Expression Correlation With Clinical Parameters

  18. PHBI: Expression Correlation With Clinical Parameters

  19. Sources of Reproducibility (Experimental Design- Randomization) C4 Hybridized Sample B & A1 (Day 1); A6 & A15 (Day 2) [while same day samples had very similar #DE genes as C1, C2, and C3] C5 Hybridized Samples B & A1 (Day 1); A6 (Day 2); A15 (Day 3) C2 and C3 Stored Male Arrays ON, 4oC while Female Arrays were Wash/Stain (Yang et al 2008)

  20. Sources of Reproducibility (Experimental Design- Randomization) Each dataset is self-consistent Training on Center 3 generally groups M and F by sample type Training on Center 4 produces poor correlation between M and F by sample type (Yang et al 2008)

  21. Stability of Results Critical Review of Published Microarray Studies for Cancer Outcome and Guidelines on Statistical Analysis and Reporting Alain Dupuy , Richard M . Simon (JNCI 2007) “Simon Says Top 40”

  22. Nature Biotechnology 28, 827 (2010)

  23. Experimental Design and Questions Summary Signal Intensities Before and After Normalization PCA plots Significant Genes Listing including FC, p-value, FDR analysis Cluster Diagram (+/- Signal Intensities) Over-represented Gene Ontology Categories RDAVID?? Experimental Conclusions and Discussion Affymetrix Gene Expression MicroarraysReport Expectations

  24. Affymetrix Gene Expression MicroarraysReport Expectations

More Related